Dog Hemangiosarcoma: Welfare at End of Life

Hemangiosarcoma is an aggressive blood vessel cancer in dogs, most common in the spleen. Its typically late diagnosis and rapid progression make welfare-focused end-of-life care essential.

Key Facts

Hemangiosarcoma (HSA) is among the most aggressive canine cancers, with median survival of 2-3 months even with treatment
The spleen is the most common site; cardiac HSA carries an even worse prognosis
Many dogs present with acute internal hemorrhage (ruptured splenic HSA) — an emergency requiring immediate surgery
Golden Retrievers, German Shepherds, and Labrador Retrievers are most commonly affected
Emergency splenectomy buys time (median 1-2 months) but does not cure the disease
Chemotherapy (doxorubicin protocol) extends median survival to approximately 4-6 months in some cases

Welfare Considerations

HSA welfare management requires honest early conversations about prognosis and quality of life expectations. Emergency splenectomy is appropriate to address acute hemorrhage and assess whether the dog is a candidate for further treatment, but owners must understand they are buying weeks to months, not years. Dogs with HSA often maintain good quality of life between episodes, making timing of euthanasia challenging. Welfare-centered end-of-life management focuses on maintaining comfort, recognizing declining quality of life, and ensuring euthanasia occurs before significant suffering rather than after.

What You Can Do

Discuss prognosis and quality-of-life expectations honestly with your veterinarian before pursuing treatment
Establish quality-of-life assessment criteria in advance to guide end-of-life timing decisions
Provide maximum comfort care during whatever time remains — pain management, gentle exercise, favorite activities
Choose timely, peaceful euthanasia before significant suffering occurs rather than waiting for crisis